A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for
the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk
MDS.